← All Anteris Technologies Global CORP filings

Anteris Technologies Global CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
AVR
Anteris Technologies Global CORP
10-K: Anteris Technologies Advances DurAVR Trial, Secures $320M Funding
Anteris Technologies Global Corp. reported significant R&D investments and net losses in 2025, while successfully initiating its pivotal PARADIGM Trial and securing substantial capital raises in late 2025 and early 2026.
NASDAQ
AVR
Anteris Technologies Global CORP
10-K/A: Anteris Technologies Files Amendment to 10-K to Include Omitted Information on Directors, Executive Compensation, and Related Matters
Anteris Technologies files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, and related corporate governance matters.
NASDAQ
AVR
Anteris Technologies Global CORP
10-K: Anteris Technologies Global Corp. Navigates Development Stage with Focus on DurAVR THV System
Anteris Technologies Global Corp.'s 10-K filing highlights its ongoing development of the DurAVR THV system, clinical trial progress, and financial position as a development-stage company.